Promising prostate cancer drug apalutamide tested in chinese patients

NCT ID NCT04108208

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests whether the drug apalutamide can delay prostate cancer progression in Chinese men whose cancer has stopped responding to standard hormone therapy but hasn't spread to other parts of the body. About 75 participants will receive either apalutamide or a placebo, alongside ongoing hormone therapy. The main goal is to see how long it takes for a key cancer marker (PSA) to rise, indicating progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apalutamide
What this could lead to: If successful, this could provide a new treatment option for Chinese men with prostate cancer that has stopped responding to hormone therapy but hasn't spread, potentially delaying disease progression.
What could go wrong: This is a relatively small, early-stage trial (75 participants) focused on a biomarker (PSA) rather than survival or metastasis. The drug may not show meaningful benefit or could cause side effects like fatigue, falls, or fractures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

Beijing Friendship Hospital

Beijing, 100050, China
Beijing Hospital

Beijing, 100730, China
Cancer Hospital Chinese Academy of Medical Sciences

Beijing, 100021, China
Cancer Hospital, FuDan University

Shanghai, 200032, China
Chongqing University Cancer Hospital

Chongqing, 400030, China
First Affiliated Hospital SooChow University

Suzhou, 215006, China
Fujian Medical University Union Hospital

Fuzhou, 350001, China
Guangzhou First Municipal People's Hospital

Guangzhou, 510180, China
Huadong Hospital Affiliated to Fudan University

Shanghai, 200400, China
Huashan Hospital Fudan University

Shanghai, 200040, China
Hunan Cancer hospital

Changsha, 410013, China
Nanjing Drum Tower Hospital

Nanjing, 210008, China
Peking University First Hospital

Beijing, 100034, China
Peking University People's Hospital

Beijing, 100044, China
Peking University Third Hospital

Beijing, 100191, China
Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, 200240, China
Shanghai Zhongshan Hospital

Shanghai, 200032, China
Sichuan Provincial Peoples Hospital

Chengdu, 610072, China
Sun Yat-Sen Memorial Hospital Sun Yat-sen University

Guangzhou, 510120, China
The Fifth People's Hospital of Shanghai, Fudan University

Shanghai, 200240, China
The First Affiliated Hospital Zhejiang University College of Medicine

Hangzhou, 310003, China
The First Affiliated Hospital of Ningbo University

Ningbo, 315010, China
The First Affiliated Hospital of Xian Jiaotong University

Xi'an, 710061, China
TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology

Wuhan, 430030, China
Wuxi People s Hospital

Wuxi, 214023, China
Zhejiang Cancer Hospital

Hangzhou, 310022, China
Zhejiang Provincial People's Hospital

Hangzhou, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.